Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines

<p class="MsoNoSpacing"><span style="font-size: 7.5pt; font-family: Verdana, sans-serif; background-position: initial initial; background-repeat: initial initial;">Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries...

Full description

Bibliographic Details
Main Authors: Diana C Otczyk, Allan W Cripps
Format: Article
Language:English
Published: BMC 2013-01-01
Series:Pneumonia
Subjects:
Online Access:https://pneumonia.org.au/index.php/pneumonia/article/view/229
id doaj-aa8d1daf12834d7faded0e891b15afdb
record_format Article
spelling doaj-aa8d1daf12834d7faded0e891b15afdb2020-11-25T01:13:32ZengBMCPneumonia2200-61332013-01-012021510.15172/pneu.2013.2/229192Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccinesDiana C Otczyk0Allan W Cripps1Menzies Health Instutute, Griffith UniversityGriffith University<p class="MsoNoSpacing"><span style="font-size: 7.5pt; font-family: Verdana, sans-serif; background-position: initial initial; background-repeat: initial initial;">Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries, as well as in many indigenous communities within developed nations. Haemophilus influenzae type b and Streptococcus pneumoniae conjugate vaccines are currently available against the leading bacterial causes of pneumonia.  The use of the vaccines in both industrialised and developing countries have shown a dramatic reduction in the burden of pneumonia and invasive disease in children.  However, the greatest threat facing pneumococcal conjugate vaccine effectiveness is serotype replacement.  The current vaccines provide serotype-specific, antibody–mediated protection against only a few of the 90+ capsule serotypes.  Therefore, there has been a focus in recent years to rapidly advance technologies that will result in broader disease coverage and more affordable vaccines that can be used in developing countries.  The next generation of pneumococcal vaccines have advanced to clinical trials.</span></p>https://pneumonia.org.au/index.php/pneumonia/article/view/229pneumonia, bacteria, Haemophilus influenzae type b, Streptococcus pneumoniae, vaccine, WHO.
collection DOAJ
language English
format Article
sources DOAJ
author Diana C Otczyk
Allan W Cripps
spellingShingle Diana C Otczyk
Allan W Cripps
Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
Pneumonia
pneumonia, bacteria, Haemophilus influenzae type b, Streptococcus pneumoniae, vaccine, WHO.
author_facet Diana C Otczyk
Allan W Cripps
author_sort Diana C Otczyk
title Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
title_short Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
title_full Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
title_fullStr Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
title_full_unstemmed Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
title_sort vaccination for the control of childhood bacterial pneumonia - haemophilus influenzae type b and pneumococcal vaccines
publisher BMC
series Pneumonia
issn 2200-6133
publishDate 2013-01-01
description <p class="MsoNoSpacing"><span style="font-size: 7.5pt; font-family: Verdana, sans-serif; background-position: initial initial; background-repeat: initial initial;">Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries, as well as in many indigenous communities within developed nations. Haemophilus influenzae type b and Streptococcus pneumoniae conjugate vaccines are currently available against the leading bacterial causes of pneumonia.  The use of the vaccines in both industrialised and developing countries have shown a dramatic reduction in the burden of pneumonia and invasive disease in children.  However, the greatest threat facing pneumococcal conjugate vaccine effectiveness is serotype replacement.  The current vaccines provide serotype-specific, antibody–mediated protection against only a few of the 90+ capsule serotypes.  Therefore, there has been a focus in recent years to rapidly advance technologies that will result in broader disease coverage and more affordable vaccines that can be used in developing countries.  The next generation of pneumococcal vaccines have advanced to clinical trials.</span></p>
topic pneumonia, bacteria, Haemophilus influenzae type b, Streptococcus pneumoniae, vaccine, WHO.
url https://pneumonia.org.au/index.php/pneumonia/article/view/229
work_keys_str_mv AT dianacotczyk vaccinationforthecontrolofchildhoodbacterialpneumoniahaemophilusinfluenzaetypebandpneumococcalvaccines
AT allanwcripps vaccinationforthecontrolofchildhoodbacterialpneumoniahaemophilusinfluenzaetypebandpneumococcalvaccines
_version_ 1725161696159334400